Preparation method of high-purity L-valine
By using multiple cation exchange resin columns connected in series and activated carbon decolorization, the safety hazards and long production cycle in the valine purification process were solved, achieving the preparation of high-purity valine and improving production efficiency.
Patent Information
- Application Number
- CN202411092355.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-09
- Publication Date
- 2024-11-22
AI Technical Summary
Current valine production processes require the use of flocculants during purification, posing safety risks, and have long production cycles, failing to meet the requirements for pharmaceutical-grade products.
Purification is achieved by using multiple cation exchange resin columns connected in series, combined with activated carbon decolorization and vacuum concentration crystallization, avoiding the use of flocculants, and ensuring production continuity through the recycling of cation exchange resin columns.
This method enables the preparation of high-purity valine, avoids the safety hazards associated with flocculants, shortens the production cycle, reduces costs, and ensures production stability and capacity.
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of separation and purification of amino acids, and in particular to a method for preparing high-purity L-valine. Background Art
[0002] L-valine, a branched amino acid, is one of the essential amino acids for the human body and is widely used in medicine, food, flavoring and other fields. Currently, in the field of medicine, valine is often used to make compound amino acid infusion and amino acid oral solution for the treatment of chronic liver cirrhosis, diabetes and other related diseases.
[0003] At present, the main method for producing valine is fermentation, which uses glucose as a nutrient and produces valine after corresponding enzyme fermentation. However, at the end of fermentation, the fermentation liquid contains amino acids such as leucine and alanine in addition to valine. Therefore, valine needs to be purified.
[0004] Nowadays, valine is usually purified by ion exchange, but this method requires the use of flocculants. Therefore, for valine used in the pharmaceutical field, it will bring safety risks to pharmaceutical-grade products.
[0005] Secondly, during the purification process, membrane filtration and membrane separation are required, so the production cycle is relatively long. Summary of the invention
[0006] In view of the shortcomings of the prior art, the object of the present invention is to provide a method for preparing high-purity L-valine, aiming to solve the problems arising from the above-mentioned background technology.
[0007] The technical solution of the present invention is achieved as follows: a method for preparing high-purity L-valine, characterized in that it comprises the following steps:
[0008] S1: preparing an aqueous solution with a weight percentage concentration of 3-4% by weight at 80-90° C.
[0009] S2: After the water in step S1 is easily completely dissolved, add an appropriate amount of hydrochloric acid to adjust the pH to 4.5-6.5, and add 0.5-1% of the weight of the filtrate activated carbon, stir and decolorize for 1 hour, then filter to obtain the upper column liquid;
[0010] S3: Cooling the column liquid obtained in step S2 to 30-45° C. and applying the column liquid to a cation exchange lipid column, wherein the diameter-to-height ratio of the cation exchange lipid column is 1:5-10;
[0011] S4: collecting the collected liquid from the cation exchange lipid column, concentrating it to 1 / 3 of the original volume, adding 0.2-0.5% activated carbon for decolorization and filtering to obtain a filtrate;
[0012] S5: The filtrate obtained in step S4 is microfiltered and then vacuum concentrated, cooled for crystallization, and solid-liquid separated to obtain a pharmaceutical grade valine crystalline product.
[0013] Preferably, there are at least three cation exchange lipid columns in step S3.
[0014] Preferably, step S3 also includes a method for using a cation exchange lipid column, comprising the following steps:
[0015] S-1: The liquid is loaded onto the first cation exchange lipid column, and when the ninhydrin color is developed in the liquid out of the first cation exchange lipid column, it is transferred to the second cation exchange lipid column;
[0016] S-2: When the effluent of the second cation exchange lipid column in step S-1 is colored by ninhydrin, collection is started to obtain the collected solution in step S4;
[0017] S-3: Detect the purity of valine at the end of the second cation exchange lipid column in step S-1. When the purity of valine is lower than the standard, transfer the column liquid at the end of the second cation exchange lipid column in step S-1 to the third cation exchange lipid column, and transfer the column liquid in step S-1 to the second cation exchange lipid column, and start the column loading with the second cation exchange lipid column;
[0018] S-4: When the effluent of the third cation exchange lipid column in step S-3 is colored by ninhydrin, collection is started to obtain the collected solution in step S4;
[0019] S-5: The purity of valine at the end of the third cation exchange lipid column in step S-4 is detected. When the purity of valine is lower than the standard, the column liquid at the end of the third cation exchange lipid column in step S-4 is transferred to the first cation exchange lipid column, and the column liquid in step S-3 is transferred to the third cation exchange lipid column, and the column loading is started from the third cation exchange lipid column;
[0020] S-6: When the effluent of the first cation exchange lipid column in step S-5 is colored by ninhydrin, collection is started to obtain the collected solution in step S4;
[0021] S-7: Detect the purity of valine at the end of the first cation exchange lipid column in step S-6. When the purity of valine is lower than the standard, proceed to step S-1.
[0022] Preferably, in step S-3 and / or step S-4, the first cation exchange lipid column is eluted, regenerated and rinsed in sequence.
[0023] Preferably, in step S-5 and / or step S-6, the second cation exchange lipid column is eluted, regenerated and rinsed in sequence.
[0024] Preferably, in step S-1 and / or step S-2, the third cation exchange lipid column is sequentially subjected to air elution, regeneration and elution.
[0025] The present invention has at least the following beneficial effects:
[0026] 1. No flocculant is used in the preparation process of L-valine of the present invention, thereby avoiding potential safety hazards to pharmaceutical-grade products.
[0027] 2. The present invention does not require membrane filtration and membrane separation, thereby shortening the production cycle and reducing production costs.
[0028] 3. The present invention utilizes a plurality of cation exchange lipid columns connected in series, which can be recycled to ensure continuous and stable production and the production capacity of the enterprise. DETAILED DESCRIPTION
[0029] The following will be combined with the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0030] The present invention discloses a method for preparing high-purity L-valine, which is characterized by comprising the following steps:
[0031] S1: preparing an aqueous solution with a weight percentage concentration of 3-4% by weight at 80-90° C.
[0032] S2: After the water in step S1 is easily completely dissolved, add an appropriate amount of hydrochloric acid to adjust the pH to 4.5-6.5, and add 0.5-1% of the weight of the filtrate activated carbon, stir and decolorize for 1 hour, then filter to obtain the upper column liquid;
[0033] S3: Cooling the column liquid obtained in step S2 to 30-45° C. and applying the column liquid to a cation exchange lipid column, wherein the diameter-to-height ratio of the cation exchange lipid column is 1:5-10;
[0034] S4: collecting the collected liquid from the cation exchange lipid column, concentrating it to 1 / 3 of the original volume, adding 0.2-0.5% activated carbon for decolorization and filtering to obtain a filtrate;
[0035] S5: The filtrate obtained in step S4 is microfiltered and then vacuum concentrated, cooled for crystallization, and solid-liquid separated to obtain a pharmaceutical grade valine crystalline product.
[0036] In this embodiment: there are three cation exchange lipid columns in step S3.
[0037] In this embodiment: step S3 also includes a method for using a cation exchange lipid column, comprising the following steps:
[0038] S-1: The liquid is loaded onto the first cation exchange lipid column, and when the ninhydrin color is developed in the liquid out of the first cation exchange lipid column, it is transferred to the second cation exchange lipid column;
[0039] S-2: When the effluent of the second cation exchange lipid column in step S-1 is colored by ninhydrin, collection is started to obtain the collected solution in step S4;
[0040] S-3: Detect the purity of valine at the end of the second cation exchange lipid column in step S-1. When the purity of valine is lower than the standard, transfer the column liquid at the end of the second cation exchange lipid column in step S-1 to the third cation exchange lipid column, and transfer the column liquid in step S-1 to the second cation exchange lipid column, and start the column loading with the second cation exchange lipid column;
[0041] S-4: When the effluent of the third cation exchange lipid column in step S-3 is colored by ninhydrin, collection is started to obtain the collected solution in step S4;
[0042] S-5: The purity of valine at the end of the third cation exchange lipid column in step S-4 is detected. When the purity of valine is lower than the standard, the column liquid at the end of the third cation exchange lipid column in step S-4 is transferred to the first cation exchange lipid column, and the column liquid in step S-3 is transferred to the third cation exchange lipid column, and the column loading is started from the third cation exchange lipid column;
[0043] S-6: When the effluent of the first cation exchange lipid column in step S-5 is colored by ninhydrin, collection is started to obtain the collected solution in step S4;
[0044] S-7: Detect the purity of valine at the end of the first cation exchange lipid column in step S-6. When the purity of valine is lower than the standard, proceed to step S-1.
[0045] In this embodiment: in step S-3 and / or step S-4, the first cation exchange lipid column is eluted, regenerated and rinsed in sequence.
[0046] In this embodiment: in step S-5 and / or step S-6, the second cation exchange lipid column is eluted, regenerated and rinsed in sequence.
[0047] In this embodiment: in step S-1 and / or step S-2, the third cation exchange lipid column is sequentially eluted, regenerated and rinsed with air.
[0048] In this embodiment, the cleaning of the cation exchange lipid column is mainly concentrated in the idle time of the cation exchange lipid column, which can ensure the recycling of the cation exchange lipid column and provide guarantee for continuous production.
[0049] The relevant test data of this embodiment are as follows:
[0050] Test items Requirement Standards Industry average This embodiment Alanine ≤0.1% 0.02% 0.007%-0.008% Phenylalanine ≤0.1% 0.01% 0.001% Isoleucine ≤0.1% 0.06% 0.032%-0.046% Leucine ≤0.1% 0.02% 0.003%-0.009% Total ≤0.2% 0.11% 0.044%-0.061% Flocculants ≤0.002% 0.0018 Not detected
[0051] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the protection scope of the present invention.
Claims
1. A method for preparing high-purity L-valine, Features: The steps include: S1: preparing an aqueous solution with a weight percentage concentration of 3-4% by weight at 80-90° C. S2: After the water in step S1 is easily completely dissolved, add an appropriate amount of hydrochloric acid to adjust the pH to 4.5-6.5, and add 0.5-1% of the weight of the filtrate activated carbon, stir and decolorize for 1 hour, then filter to obtain the upper column liquid; S3: Cooling the column liquid obtained in step S2 to 30-45° C. and applying the column liquid to a cation exchange lipid column, wherein the diameter-to-height ratio of the cation exchange lipid column is 1:5-10; S4: collecting the collected liquid from the cation exchange lipid column, concentrating it to 1 / 3 of the original volume, adding 0.2-0.5% activated carbon for decolorization and filtering to obtain a filtrate; S5: The filtrate obtained in step S4 is microfiltered and then vacuum concentrated, cooled for crystallization, and solid-liquid separated to obtain a pharmaceutical grade valine crystalline product.
2. A method for preparing high-purity L-valine according to claim 1, Features: There are at least three cation exchange lipid columns in step S3.
3. A method for preparing high-purity L-valine according to claim 2, Features: Step S3 also includes a method for using a cation exchange lipid column, comprising the following steps: S-1: The liquid is loaded onto the first cation exchange lipid column, and when the ninhydrin color is developed in the liquid out of the first cation exchange lipid column, it is transferred to the second cation exchange lipid column; S-2: When the effluent of the second cation exchange lipid column in step S-1 is colored by ninhydrin, collection is started to obtain the collected solution in step S4; S-3: Detect the purity of valine at the end of the second cation exchange lipid column in step S-1. When the purity of valine is lower than the standard, transfer the column liquid at the end of the second cation exchange lipid column in step S-1 to the third cation exchange lipid column, and transfer the column liquid in step S-1 to the second cation exchange lipid column, and start the column loading with the second cation exchange lipid column; S-4: When the effluent of the third cation exchange lipid column in step S-3 is colored by ninhydrin, collection is started to obtain the collected solution in step S4; S-5: The purity of valine at the end of the third cation exchange lipid column in step S-4 is detected. When the purity of valine is lower than the standard, the column liquid at the end of the third cation exchange lipid column in step S-4 is transferred to the first cation exchange lipid column, and the column liquid in step S-3 is transferred to the third cation exchange lipid column, and the column loading is started from the third cation exchange lipid column; S-6: When the effluent of the first cation exchange lipid column in step S-5 is colored by ninhydrin, collection is started to obtain the collected solution in step S4; S-7: Detect the purity of valine at the end of the first cation exchange lipid column in step S-6. When the purity of valine is lower than the standard, proceed to step S-1.
4. A method for preparing high-purity L-valine according to claim 3, Features: In step S-3 and / or step S-4, the first cation exchange lipid column is eluted, regenerated and rinsed in sequence.
5. A method for preparing high-purity L-valine according to claim 3 or 4, Features: In step S-5 and / or step S-6, the second cation exchange lipid column is eluted, regenerated and rinsed in sequence.
6. A method for preparing high-purity L-valine according to claim 3 or 4, Features: In step S-1 and / or step S-2, the third cation exchange lipid column is sequentially eluted with air, regenerated and rinsed.
